AstraZeneca Korea Announces Korean Approval of Ultomiris (Ravulizumab) for AQP4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)

Jul 15, 2024 20:00 CST Updated 20:00

AstraZeneca

Biopharmaceutical Manufacturer

July 11, 2024

AstraZeneca Korea (CEO and President Jeon Se-hwan) announced that Ultomiris injection, a C5 complement inhibitor for anti-aquaporin-4 (AQP4) in adults aged 18 and over, has received additional approval from the Ministry of Food and Drug Safety for the treatment of neuromyelitis optica spectrum disorder (NMOSD) positive for AQP4 antibodies.

Ultomiris (ravulizumab-cwvz)

Ravulizumab is a new generation C5 complement inhibitor, with a half-life approximately four times that of Soliris. While Soliris requires dosing every two weeks, Ultomiris extends the dosing interval to eight weeks, thereby enhancing treatment convenience.

In South Korea, Ultomiris has been approved for use in four rare diseases, including:

Paroxysmal Nocturnal Hemoglobinuria (PNH)
Atypical Hemolytic Uremic Syndrome
Generalized Myasthenia Gravis (gMG)
Neuromyelitis Optica Spectrum Disorders (NMOSD)

Source| Baipei Health

Editor | Subi

Rare Neurological Disorders Communication Group

↓Click " belowRead the Original Text", DownloadMedSci Medical APP!